Analysis of the Bile Acid Composition in a Fibroblast Growth Factor 19-Expressing Liver-Humanized Mouse Model and Its Use for CYP3A4-Mediated Drug-Drug Interaction Studies.

Mice Humans Animals Bile Acids and Salts / metabolism Cytochrome P-450 CYP3A / genetics Mice, Inbred NOD Liver / metabolism Disease Models, Animal Fibroblast Growth Factors / metabolism Drug Interactions

Journal

Drug metabolism and disposition: the biological fate of chemicals
ISSN: 1521-009X
Titre abrégé: Drug Metab Dispos
Pays: United States
ID NLM: 9421550

Informations de publication

Date de publication:
10 2023
Historique:
received: 16 05 2023
accepted: 13 07 2023
medline: 18 9 2023
pubmed: 1 8 2023
entrez: 31 7 2023
Statut: ppublish

Résumé

Numerous biomedical applications have been described for liver-humanized mouse models, such as in drug metabolism or drug-drug interaction (DDI) studies. However, the strong enlargement of the bile acid (BA) pool due to lack of recognition of murine intestine-derived fibroblast growth factor-15 by human hepatocytes and a resulting upregulation in the rate-controlling enzyme for BA synthesis, cytochrome P450 (CYP) 7A1, may pose a challenge in interpreting the results obtained from such mice. To address this challenge, the human fibroblast growth factor-19 (FGF19) gene was inserted into the

Identifiants

DOI: 10.1124/dmd.123.001398 PMID: 37524541
pubmed: 37524541
pii: dmd.123.001398
doi: 10.1124/dmd.123.001398
doi:

Substances chimiques

Bile Acids and Salts 0
Cytochrome P-450 CYP3A EC 1.14.14.1
Fibroblast Growth Factors 62031-54-3
CYP3A4 protein, human EC 1.14.14.55

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1391-1402

Informations de copyright

Copyright © 2023 by The American Society for Pharmacology and Experimental Therapeutics.

Auteurs

Mario Mezler (M)

Quantitative, Translational & ADME Sciences, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (R.S.J., D.S., J.C.C.); Yecuris Corporation, Tualatin, Oregon (D.C.G., L.F.); Clinical Pharmacology, Pharmacometrics, Disposition & Bioanalysis, Bristol Myers Squibb, Lawrenceville, New Jersey (M.H.); Symeres Finland Oy, Oulu, Finland, operating under Admescope brand (A.T.H., J.M.); Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. Cambridge, Massachusetts (S.P., P.P.C.); and FH Aachen University of Applied Sciences, Jülich, Germany (N.S.) mario.mezler@abbvie.com.

Robert S Jones (RS)

Quantitative, Translational & ADME Sciences, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (R.S.J., D.S., J.C.C.); Yecuris Corporation, Tualatin, Oregon (D.C.G., L.F.); Clinical Pharmacology, Pharmacometrics, Disposition & Bioanalysis, Bristol Myers Squibb, Lawrenceville, New Jersey (M.H.); Symeres Finland Oy, Oulu, Finland, operating under Admescope brand (A.T.H., J.M.); Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. Cambridge, Massachusetts (S.P., P.P.C.); and FH Aachen University of Applied Sciences, Jülich, Germany (N.S.).
ORCID: 0000-0002-7253-0962

Dewakar Sangaraju (D)

Quantitative, Translational & ADME Sciences, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (R.S.J., D.S., J.C.C.); Yecuris Corporation, Tualatin, Oregon (D.C.G., L.F.); Clinical Pharmacology, Pharmacometrics, Disposition & Bioanalysis, Bristol Myers Squibb, Lawrenceville, New Jersey (M.H.); Symeres Finland Oy, Oulu, Finland, operating under Admescope brand (A.T.H., J.M.); Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. Cambridge, Massachusetts (S.P., P.P.C.); and FH Aachen University of Applied Sciences, Jülich, Germany (N.S.).
ORCID: 0000-0002-5283-8070

Devorah C Goldman (DC)

Quantitative, Translational & ADME Sciences, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (R.S.J., D.S., J.C.C.); Yecuris Corporation, Tualatin, Oregon (D.C.G., L.F.); Clinical Pharmacology, Pharmacometrics, Disposition & Bioanalysis, Bristol Myers Squibb, Lawrenceville, New Jersey (M.H.); Symeres Finland Oy, Oulu, Finland, operating under Admescope brand (A.T.H., J.M.); Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. Cambridge, Massachusetts (S.P., P.P.C.); and FH Aachen University of Applied Sciences, Jülich, Germany (N.S.).

Matthew Hoffmann (M)

Quantitative, Translational & ADME Sciences, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (R.S.J., D.S., J.C.C.); Yecuris Corporation, Tualatin, Oregon (D.C.G., L.F.); Clinical Pharmacology, Pharmacometrics, Disposition & Bioanalysis, Bristol Myers Squibb, Lawrenceville, New Jersey (M.H.); Symeres Finland Oy, Oulu, Finland, operating under Admescope brand (A.T.H., J.M.); Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. Cambridge, Massachusetts (S.P., P.P.C.); and FH Aachen University of Applied Sciences, Jülich, Germany (N.S.).

Aki T Heikkinen (AT)

Quantitative, Translational & ADME Sciences, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (R.S.J., D.S., J.C.C.); Yecuris Corporation, Tualatin, Oregon (D.C.G., L.F.); Clinical Pharmacology, Pharmacometrics, Disposition & Bioanalysis, Bristol Myers Squibb, Lawrenceville, New Jersey (M.H.); Symeres Finland Oy, Oulu, Finland, operating under Admescope brand (A.T.H., J.M.); Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. Cambridge, Massachusetts (S.P., P.P.C.); and FH Aachen University of Applied Sciences, Jülich, Germany (N.S.).

Janne Mannila (J)

Quantitative, Translational & ADME Sciences, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (R.S.J., D.S., J.C.C.); Yecuris Corporation, Tualatin, Oregon (D.C.G., L.F.); Clinical Pharmacology, Pharmacometrics, Disposition & Bioanalysis, Bristol Myers Squibb, Lawrenceville, New Jersey (M.H.); Symeres Finland Oy, Oulu, Finland, operating under Admescope brand (A.T.H., J.M.); Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. Cambridge, Massachusetts (S.P., P.P.C.); and FH Aachen University of Applied Sciences, Jülich, Germany (N.S.).

Jae H Chang (JH)

Quantitative, Translational & ADME Sciences, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (R.S.J., D.S., J.C.C.); Yecuris Corporation, Tualatin, Oregon (D.C.G., L.F.); Clinical Pharmacology, Pharmacometrics, Disposition & Bioanalysis, Bristol Myers Squibb, Lawrenceville, New Jersey (M.H.); Symeres Finland Oy, Oulu, Finland, operating under Admescope brand (A.T.H., J.M.); Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. Cambridge, Massachusetts (S.P., P.P.C.); and FH Aachen University of Applied Sciences, Jülich, Germany (N.S.).

Lander Foquet (L)

Quantitative, Translational & ADME Sciences, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (R.S.J., D.S., J.C.C.); Yecuris Corporation, Tualatin, Oregon (D.C.G., L.F.); Clinical Pharmacology, Pharmacometrics, Disposition & Bioanalysis, Bristol Myers Squibb, Lawrenceville, New Jersey (M.H.); Symeres Finland Oy, Oulu, Finland, operating under Admescope brand (A.T.H., J.M.); Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. Cambridge, Massachusetts (S.P., P.P.C.); and FH Aachen University of Applied Sciences, Jülich, Germany (N.S.).
ORCID: 0000-0003-3457-7695

Sandeepraj Pusalkar (S)

Quantitative, Translational & ADME Sciences, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (R.S.J., D.S., J.C.C.); Yecuris Corporation, Tualatin, Oregon (D.C.G., L.F.); Clinical Pharmacology, Pharmacometrics, Disposition & Bioanalysis, Bristol Myers Squibb, Lawrenceville, New Jersey (M.H.); Symeres Finland Oy, Oulu, Finland, operating under Admescope brand (A.T.H., J.M.); Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. Cambridge, Massachusetts (S.P., P.P.C.); and FH Aachen University of Applied Sciences, Jülich, Germany (N.S.).

Paresh P Chothe (PP)

Quantitative, Translational & ADME Sciences, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (R.S.J., D.S., J.C.C.); Yecuris Corporation, Tualatin, Oregon (D.C.G., L.F.); Clinical Pharmacology, Pharmacometrics, Disposition & Bioanalysis, Bristol Myers Squibb, Lawrenceville, New Jersey (M.H.); Symeres Finland Oy, Oulu, Finland, operating under Admescope brand (A.T.H., J.M.); Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. Cambridge, Massachusetts (S.P., P.P.C.); and FH Aachen University of Applied Sciences, Jülich, Germany (N.S.).

Nico Scheer (N)

Quantitative, Translational & ADME Sciences, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M.); Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California (R.S.J., D.S., J.C.C.); Yecuris Corporation, Tualatin, Oregon (D.C.G., L.F.); Clinical Pharmacology, Pharmacometrics, Disposition & Bioanalysis, Bristol Myers Squibb, Lawrenceville, New Jersey (M.H.); Symeres Finland Oy, Oulu, Finland, operating under Admescope brand (A.T.H., J.M.); Global Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc. Cambridge, Massachusetts (S.P., P.P.C.); and FH Aachen University of Applied Sciences, Jülich, Germany (N.S.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Analysis of the Bile Acid Composition in a...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Analysis of the Bile Acid Composition in a...
questionsmedicales.fr › Eucaryotes › Animaux › Analysis of the Bile Acid Composition in a...
questionsmedicales.fr › Composés polycycliques › Composés à cycles fusionnés › Stéroïdes › Acides et sels biliaires › Analysis of the Bile Acid Composition in a...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Hémoprotéines › Cytochromes › Cytochrome P-450 enzyme system › Famille-3 de cytochromes P450 › Cytochrome P-450 CYP3A › Analysis of the Bile Acid Composition in a...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée NOD › Analysis of the Bile Acid Composition in a...
questionsmedicales.fr › Système digestif › Foie › Analysis of the Bile Acid Composition in a...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Analysis of the Bile Acid Composition in a...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Facteurs de croissance fibroblastique › Analysis of the Bile Acid Composition in a...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Interactions médicamenteuses › Analysis of the Bile Acid Composition in a...